Heartseed株式会社 Logo

Heartseed株式会社

Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.

219A | T

Overview

Corporate Details

ISIN(s):
JP3765140003
LEI:
Country:
Japan
Address:
港区芝浦1丁目2番3号シーバンスS館5階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Heartseed Inc. is a clinical-stage biotechnology company specializing in regenerative medicine for cardiac diseases. Founded in 2015 as a spin-off from Keio University, the company develops iPSC-derived cell therapies for severe heart failure. Its core strategy is "remuscularization," a novel approach to regenerate damaged heart tissue by transplanting highly purified cardiomyocyte spheroids. The lead pipeline product, HS-001, is an allogeneic iPSC-derived cardiomyocyte therapy administered via intramyocardial injection for patients with heart failure with reduced ejection fraction (HFrEF). Heartseed aims to provide a fundamental treatment for conditions where heart transplantation was previously the only curative option. The company also conducts research on next-generation therapies using autologous and HLA-edited iPSCs to minimize immune rejection.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-19 09:00
Major Shareholding Notification
臨時報告書
Japanese 19.9 KB
2025-06-12 08:30
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-06-12 08:30
Interim Report
半期報告書-第10期(2024/11/01-2025/12/31)
Japanese 143.9 KB
2025-01-27 02:01
Post-Annual General Meeting Information
臨時報告書
Japanese 21.3 KB
2025-01-27 02:01
Registration Form
確認書
Japanese 8.0 KB
2025-01-27 02:00
Annual Report
有価証券報告書-第9期(2023/11/01-2024/10/31)
Japanese 6.0 MB
2025-01-27 02:00
Governance Information
内部統制報告書-第9期(2023/11/01-2024/10/31)
Japanese 21.1 KB
2024-07-22 08:18
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 4.6 MB
2024-07-11 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 4.6 MB
2024-06-26 08:00
Registration Form
有価証券届出書(新規公開時)
Japanese 9.0 MB

Automate Your Workflow. Get a real-time feed of all Heartseed株式会社 filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Heartseed株式会社

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Heartseed株式会社 via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.